CRR_Call Tracker

Text/HTML

Text/HTML

ValueProductView

ValueProductPastPerformance

Company NameReco DateReco PriceExit PriceExit Date% ReturnIn days
Bharat Forge Ltd. 25/07/20241,593.85952.3007/04/2025 -40.25% 256 days
ITC Ltd. 28/12/2023464.20487.5002/01/2025 5.02% 1 yrs
Britannia Industries Ltd. 27/07/20234,875.805,028.2512/11/2024 3.13% 1 yrs
JSW Steel Ltd. 22/02/2024826.951,003.0026/09/2024 21.29% 217 days
Bajaj Auto Ltd. 22/08/20249,910.0011,930.0017/09/2024 20.38% 26 days
Dr. Reddy's Laboratories Ltd. 26/10/20235,429.306,536.0005/07/2024 20.38% 253 days
Shriram Finance Ltd. 25/04/20242,430.102,955.0028/06/2024 21.60% 64 days
Coal India Ltd. 25/01/2024389.50501.6022/05/2024 28.78% 118 days
Infosys Ltd. 27/10/20221,522.601,411.6019/04/2024 -7.29% 1 yrs
State Bank Of India 25/05/2023581.30782.0505/03/2024 34.53% 285 days

CRR_MVC_PastPerformance

Text/HTML

Our Other Trader Products

EasyDNNNews

Pharma company receives final ANDA approval for Rivaroxaban Tablets USP, 2.5mg & tentative approval for other strengths of Rivaroxaban Tablets USP

Aurobindo Pharma Limited announced obtaining the last approval from the US Food & Drug Administration (USFDA) for Rivaroxaban Tablets USP, 2.5 mg.

DSIJ Intelligence-1 0 165 Article rating: 5.0

The biosimilars division alongside niche product development represents Aurobindo Pharma's main focus areas where its 1500 scientists dedicate their efforts.

Medical Equipment & Supplies Expands Global Reach in Medical Devices; Secures USFDA Registration

Company's products are available both online, through its proprietary store and major e-commerce platforms, and offline, with a presence in over 22,000 retail touchpoints across 460+ towns in India.

DSIJ Intelligence-1 0 187 Article rating: 5.0

The company's wholly-owned subsidiary, Nureca Technologies Pvt Ltd, specializes in manufacturing medical devices with an annual capacity of 8 lakh units.

Pharma Company Has Received Final Approval From United States Food and Drug Administration For Abbreviated New Drug Application

The company has a market cap of over Rs 1 lakh crore and the stock is up by 13 per cent from its 52-week low of Rs 1,310.05 per share.

DSIJ Intelligence-1 0 428 Article rating: 4.7

The company has a market cap of over Rs 1 lakh crore and the stock is up by 13 per cent from its 52-week low of Rs 1,310.05 per share.

Multibagger Pharma Stock Rises Nearly 3 Per Cent After US FDA Observations on Telangana Facility

The inspection, conducted between December 9 and December 17, 2024, resulted in two procedural observations from the US FDA.

DSIJ Intelligence 0 221 Article rating: 4.3

The facility in question, Unit-V, is an active pharmaceutical ingredient (API) manufacturing site operated by Apitoria Pharma Private Ltd, a wholly owned subsidiary of Aurobindo Pharma, located in Pashamylaram Village, Telangana.

 

Indian Pharma Company Scores Major USFDA Approval for Game-Changing Capsule, Plans 5+ New Product Launches!

With the USFDA's green light, the Indian pharmaceutical company is poised to expand its product portfolio and strengthen its global presence

DSIJ Intelligence 0 219 Article rating: 5.0

With the USFDA's green light, the Indian pharmaceutical company is poised to expand its product portfolio and strengthen its global presence

This pharma company's shares surged to a new 52-week high after receiving final approval from the USFDA.

The share has delivered over 95 per cent returns in the past year, transforming into a multi-bagger with over 260 per cent returns in the last two years.

DSIJ Intelligence 0 351 Article rating: 3.7

The share has delivered over 95 per cent returns in the past year, transforming into a multi-bagger with over 260 per cent returns in the last two years.

This pharma company stock went 8 per cent high, do you own it?

With its shares up 8 per cent, the Indian multinational pharmaceutical company posted a net profit of Rs 130 crore in the second quarter, while its turnover increased to Rs 4,145 crore.

DSIJ Intelligence-1 0 1426 Article rating: 5.0

This pharma company stock went 8 per cent high, do you own it?                                                                                                                                                                                                       With its shares up 8 per cent, the Indian multinational pharmaceutical company posted a net profit of Rs 130 crore in the second quarter, while its turnover increased to Rs 4,145 crore.

Heavy buying seen in these small-caps that hit fresh 52 week high on August 18!

On BSE, 265 stocks have hit their upper circuits whereas 131 stocks touched their lower circuits.  

DSIJ Intelligence 0 5837 Article rating: 4.2

At 2.30 pm on Thursday, the markets were seen recovering from the day’s low as Asia- Pacific markets tumbled following the overnight cooling off of the most recent Wall Street rise.  

Lupin hit the ball out of the park! Is the tide turning in favour of the stock after this big announcement?

DSIJ Intelligence-3 0 747 Article rating: 3.7

Another interesting point is that it’s not very usual these days to see pharma stock jumping 8-9 per cent but on Tuesday, Lupin broke this jinx as it soared nearly 9 per cent. Certainly, this might have brought a million-dollar smile to the faces of Lupin investors.  

RSS

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR